fenofibrate has been researched along with Broad Beta Disease in 11 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| " We studied 23 patients with elevated plasma triglycerides to evaluate the influence of fish oil and fenofibrate therapy on hemorrheological parameters (15 patients with familial hypertriglyceridemia [FHTG] and eight with familial dysbetalipoproteinemia [FDL])." | 9.08 | Effects of n-3 fatty acids and fenofibrate on lipid and hemorrheological parameters in familial dysbetalipoproteinemia and familial hypertriglyceridemia. ( Otto, C; Richter, WO; Ritter, MM; Schwandt, P; Soennichsen, AC, 1996) |
| " We studied 23 patients with elevated plasma triglycerides to evaluate the influence of fish oil and fenofibrate therapy on hemorrheological parameters (15 patients with familial hypertriglyceridemia [FHTG] and eight with familial dysbetalipoproteinemia [FDL])." | 5.08 | Effects of n-3 fatty acids and fenofibrate on lipid and hemorrheological parameters in familial dysbetalipoproteinemia and familial hypertriglyceridemia. ( Otto, C; Richter, WO; Ritter, MM; Schwandt, P; Soennichsen, AC, 1996) |
| "Treatment with bezafibrate and micronised fenofibrate both resulted in significant reductions in the serum concentrations of total cholesterol (26." | 2.68 | Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyperlipoproteinemia. ( Feussner, G; Kurth, B; Lohrmann, J, 1997) |
| "Dysbetalipoproteinemia (dysb) and familial hypercholesterolemia (FH) are two genetic disorders giving rise to severe disturbances of lipid homeostasis and premature atherosclerosis." | 1.33 | Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia. ( Couture, P; Deshaies, Y; Gagné, C; Hogue, JC; Lamarche, B; Ruel, IL; Tremblay, AJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (36.36) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vivatrat, N | 1 |
| Barshop, BA | 1 |
| Jones, KL | 1 |
| Cho, EJ | 1 |
| Min, YJ | 1 |
| Oh, MS | 1 |
| Kwon, JE | 1 |
| Kim, JE | 1 |
| Kim, CJ | 1 |
| Tremblay, AJ | 1 |
| Lamarche, B | 1 |
| Ruel, IL | 1 |
| Hogue, JC | 1 |
| Deshaies, Y | 1 |
| Gagné, C | 1 |
| Couture, P | 1 |
| Canzler, H | 1 |
| Bojanovski, D | 1 |
| Hoffer, MJ | 1 |
| Niththyananthan, S | 1 |
| Naoumova, RP | 1 |
| Kibirige, MS | 1 |
| Frants, RR | 1 |
| Havekes, LM | 1 |
| Thompson, GR | 1 |
| Otto, C | 1 |
| Ritter, MM | 1 |
| Soennichsen, AC | 1 |
| Schwandt, P | 1 |
| Richter, WO | 1 |
| Feussner, G | 2 |
| Kurth, B | 1 |
| Lohrmann, J | 1 |
| Ziegler, R | 1 |
| Lussier-Cacan, S | 1 |
| Bard, JM | 2 |
| Boulet, L | 1 |
| Nestruck, AC | 1 |
| Grothé, AM | 2 |
| Fruchart, JC | 2 |
| Davignon, J | 2 |
| Richard, A | 1 |
| Fievet, C | 1 |
| Brown, WV | 1 |
3 trials available for fenofibrate and Broad Beta Disease
| Article | Year |
|---|---|
Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
Topics: Cholesterol; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type II | 1980 |
Effects of n-3 fatty acids and fenofibrate on lipid and hemorrheological parameters in familial dysbetalipoproteinemia and familial hypertriglyceridemia.
Topics: Adult; Blood Physiological Phenomena; Blood Viscosity; Fatty Acids, Omega-3; Female; Fenofibrate; Hu | 1996 |
Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyperlipoproteinemia.
Topics: Bezafibrate; Fenofibrate; Humans; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Lipoproteins | 1997 |
8 other studies available for fenofibrate and Broad Beta Disease
| Article | Year |
|---|---|
Severe hypertriglyceridemia and recurrent pancreatitis in a girl with type Ia glycogen storage disease and type III hyperlipoproteinemia.
Topics: Apolipoproteins E; Biopsy; Child, Preschool; Female; Fenofibrate; Glycogen Storage Disease Type I; H | 2009 |
Disappearance of angina pectoris by lipid-lowering in type III hyperlipoproteinemia.
Topics: Angina Pectoris; Atorvastatin; Drug Therapy, Combination; Electrocardiography; Exercise Test; Female | 2011 |
Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia.
Topics: Adult; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins; Fenofibrate; | 2006 |
Apolipoprotein E1-Hammersmith (Lys146-->Asn;Arg147-->Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins E; Child; Child, Preschool; Cholesterol; Cholestyra | 1996 |
[Type III hyperlipoproteinemia in idiopathic hemochromatosis].
Topics: Bloodletting; Combined Modality Therapy; Fenofibrate; Hemochromatosis; Humans; Hyperlipoproteinemia | 1990 |
Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III.
Topics: Adult; Apolipoproteins; Cholesterol, LDL; Electrophoresis; Female; Fenofibrate; Humans; Hyperlipopro | 1989 |
Effect of fenofibrate treatment on type III hyperlipoproteinemia.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II | 1987 |
Potential use of fenofibrate and other fibric acid derivatives in the clinic.
Topics: Clofibrate; Fenofibrate; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hy | 1987 |